entinostat has been researched along with Uveal Neoplasms in 3 studies
Uveal Neoplasms: Tumors or cancer of the UVEA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM)." | 9.41 | The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. ( All-Eriksson, C; Alsén, S; Andersson, B; Carneiro, A; Filges, S; Helgadottir, H; Jespersen, H; Karlsson, J; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Sah, VR; Ståhlberg, A; Stierner, U; Ullenhag, G, 2021) |
| "The PEMDAC study is a multicenter, open label phase II study assessing the efficacy of concomitant use of the PD1 inhibitor pembrolizumab and the class I HDAC inhibitor entinostat in adult patients with metastatic uveal melanoma." | 9.30 | Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. ( All-Eriksson, C; Andersson, B; Carneiro, A; Helgadottir, H; Jespersen, H; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Stierner, U; Ullenhag, G, 2019) |
| " We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM)." | 5.41 | The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. ( All-Eriksson, C; Alsén, S; Andersson, B; Carneiro, A; Filges, S; Helgadottir, H; Jespersen, H; Karlsson, J; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Sah, VR; Ståhlberg, A; Stierner, U; Ullenhag, G, 2021) |
| "The PEMDAC study is a multicenter, open label phase II study assessing the efficacy of concomitant use of the PD1 inhibitor pembrolizumab and the class I HDAC inhibitor entinostat in adult patients with metastatic uveal melanoma." | 5.30 | Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. ( All-Eriksson, C; Andersson, B; Carneiro, A; Helgadottir, H; Jespersen, H; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Stierner, U; Ullenhag, G, 2019) |
| "Malignant melanoma is a highly aggressive tumor which may occur in the skin, eye, and mucous membranes." | 1.42 | The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma. ( Agliano, F; Morabito, S; Oteri, R; Teti, D; Venza, I; Venza, M; Visalli, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ny, L | 2 |
| Jespersen, H | 2 |
| Karlsson, J | 1 |
| Alsén, S | 1 |
| Filges, S | 1 |
| All-Eriksson, C | 2 |
| Andersson, B | 2 |
| Carneiro, A | 2 |
| Helgadottir, H | 2 |
| Levin, M | 2 |
| Ljuslinder, I | 2 |
| Olofsson Bagge, R | 2 |
| Sah, VR | 1 |
| Stierner, U | 2 |
| Ståhlberg, A | 1 |
| Ullenhag, G | 2 |
| Nilsson, LM | 2 |
| Nilsson, JA | 2 |
| Venza, M | 1 |
| Visalli, M | 1 |
| Oteri, R | 1 |
| Agliano, F | 1 |
| Morabito, S | 1 |
| Teti, D | 1 |
| Venza, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma[NCT02697630] | Phase 2 | 29 participants (Actual) | Interventional | 2018-02-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for entinostat and Uveal Neoplasms
| Article | Year |
|---|---|
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Humans; Melanoma; Progression-Free Survival; Pyridine | 2021 |
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Topics: Administration, Intravenous; Administration, Oral; Antibodies, Monoclonal, Humanized; Antineoplastic | 2019 |
1 other study available for entinostat and Uveal Neoplasms
| Article | Year |
|---|---|
The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
Topics: Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Resistance, Neo | 2015 |